Literature DB >> 21712030

Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines.

Kelly S Levano1, Eric H Jung, Paraic A Kenny.   

Abstract

Infiltration of the tumor microenvironment by macrophages is associated with poor outcomes in breast cancer and other solid tumors, however the identity and roles of many of the soluble factors these macrophages produce remains to be elucidated in detail. In addition to producing angiogenic factors (e.g. VEGF), proteases (e.g. MMP9) and immunomodulatory factors (e.g. IL10) which, by modifying the local microenvironment, likely contribute to progression in the majority of solid tumors, we have evaluated the extent to which macrophage cytokines may differentially affect distinct breast cancer subtypes. We identified 23 cytokines produced in a culture model of human tumor-associated macrophages and report that basal and luminal breast cancer cell lines express different repertoires of receptors for these cytokines. These data suggest that tumor-associated macrophages make specific contributions to different breast cancer subtypes and that understanding the importance of these interactions will be crucial to developing subtype-specific therapies targeting the macrophage component of the breast tumor microenvironment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21712030     DOI: 10.1016/j.bbrc.2011.06.102

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Many Roles of CCL20: Emphasis on Breast Cancer.

Authors:  Kingsley O Osuala; Bonnie F Sloane
Journal:  Postdoc J       Date:  2014-03

2.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

3.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Authors:  Celeste Bolin; Ken Tawara; Caleb Sutherland; Jeff Redshaw; Patrick Aranda; Jim Moselhy; Robin Anderson; Cheryl L Jorcyk
Journal:  Genes Cancer       Date:  2012-02

4.  Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.

Authors:  Jacob M Smigiel; Neetha Parameswaran; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2017-01-04       Impact factor: 6.333

5.  Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.

Authors:  Ya-Qing Li; Fang-Fang Liu; Xin-Min Zhang; Xiao-Jing Guo; Mei-Jing Ren; Li Fu
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

6.  Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype.

Authors:  Young Ae Cho; Mi-Kyung Sung; Jee-Young Yeon; Jungsil Ro; Jeongseon Kim
Journal:  Cancer Res Treat       Date:  2013-09-30       Impact factor: 4.679

7.  HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.

Authors:  Damian J Junk; Benjamin L Bryson; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2014-03-26       Impact factor: 6.639

8.  Human breast cancer cells educate macrophages toward the M2 activation status.

Authors:  Sofia Sousa; Régis Brion; Minnamaija Lintunen; Pauliina Kronqvist; Jouko Sandholm; Jukka Mönkkönen; Pirkko-Liisa Kellokumpu-Lehtinen; Susanna Lauttia; Olli Tynninen; Heikki Joensuu; Dominique Heymann; Jorma A Määttä
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

Review 9.  Cancer Stem Cell Plasticity Drives Therapeutic Resistance.

Authors:  Mary R Doherty; Jacob M Smigiel; Damian J Junk; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2016-01-05       Impact factor: 6.639

10.  Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response.

Authors:  Oana Tudoran; Oana Virtic; Loredana Balacescu; Carmen Lisencu; Bogdan Fetica; Claudia Gherman; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Onco Targets Ther       Date:  2015-11-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.